In a significant development, the U.S. Food and Drug Administration has granted approval to Supernus Pharmaceuticals for its groundbreaking drug-device combination aimed at alleviating movement-related symptoms of Parkinson's disease. This innovative treatment, known as Onapgo, is set to launch in the U.S. during the second quarter of this year, sparking a 5% surge in Supernus Pharmaceuticals' stock value during early trading.
After years of perseverance, Supernus Pharmaceuticals has succeeded in securing the FDA's stamp of approval for Onapgo. Past setbacks in 2022 and 2024 were overcome, with last year's request for additional information regarding product quality and the device ultimately paving the way for the recent approval.
Onapgo, acquired by Supernus through a substantial $530 million deal in 2020, functions by continuously delivering apomorphine, a key drug for treating Parkinson's disease, under the skin. This method offers a more convenient alternative to the currently approved injections, which often require administration as frequently as every two hours. By providing a consistent delivery of apomorphine, Onapgo aims to address symptoms such as tremors and mobility issues, thereby reducing the "off episodes" experienced by Parkinson's patients as their medication wears off.
With approximately 1 million individuals in the United States living with Parkinson's disease, the approval of Onapgo marks a significant step forward in enhancing treatment options for this patient population. In clinical trials, this novel combination therapy demonstrated a remarkable reduction in daily "off episodes" compared to a placebo, showcasing its potential to significantly improve patients' quality of life.
Despite the recent approval of Abbvie's pump-based treatment Vyalev, which also targets "off episodes" in Parkinson's patients, analysts suggest that Onapgo may offer a more favorable tolerability profile. Data from various studies indicate that Onapgo is likely to result in fewer skin nodules and injection site reactions compared to existing treatments, offering a promising alternative for patients seeking improved symptom management.
Supernus Pharmaceuticals anticipates significant success for Onapgo in the U.S. market, with peak sales projected to reach between $200 million and $300 million. The approval of this innovative therapy not only underscores Supernus Pharmaceuticals' commitment to advancing Parkinson's disease treatment but also heralds a new era of hope for patients battling this challenging neurological condition.